Retatrutide Development Timeline: From Discovery to Phase 3

Introduction

The development of retatrutide (LY3437943) represents one of the most closely watched drug development programs in the metabolic disease field. From its origins in Eli Lilly’s research laboratories to its current position as a Phase 3 investigational compound, retatrutide’s journey spans nearly a decade and reflects the broader evolution of incretin-based therapeutics from single-target molecules to multi-target peptides designed to engage complementary metabolic pathways.

This article presents a chronological timeline of retatrutide’s development, documenting the key milestones, publications, and regulatory decisions that have shaped its path toward potential clinical use. Understanding this timeline provides context for where the drug stands today and what steps remain before it could reach patients.

Preclinical Discovery and Development (2016-2019)

2016-2018: Molecular Design and Discovery

The origins of retatrutide trace to Eli Lilly’s peptide therapeutics research program, where scientists were working to advance beyond the single-target GLP-1 receptor agonists that had defined the first generation of incretin-based therapies. The conceptual foundation was built on growing evidence that engaging multiple metabolic receptor pathways simultaneously could produce effects greater than the sum of their individual contributions.

The key insight driving retatrutide’s design was the potential benefit of adding glucagon receptor agonism to the already-established framework of GLP-1 and GIP receptor agonism. While tirzepatide (then LY3298176) was advancing through Eli Lilly’s pipeline as a dual GIP/GLP-1 receptor agonist, the research team explored whether a third receptor target, the glucagon receptor, could further enhance metabolic outcomes, particularly weight loss and liver fat reduction.

The molecular design challenge was substantial. The team needed to engineer a single peptide that could activate three distinct GPCRs with an appropriate potency balance: sufficient GCGR activation to drive energy expenditure and hepatic fat oxidation, but not so much as to overwhelm the glucose-lowering effects of GLP-1R and GIPR agonism. The molecule also needed to incorporate half-life extension technology (fatty acid acylation for albumin binding) to enable once-weekly dosing.

After extensive structure-activity relationship studies and iterative optimization, the team identified LY3437943 as the lead candidate. The molecule featured a carefully calibrated potency profile: high GIPR potency, moderate GLP-1R potency, and lower but pharmacologically meaningful GCGR potency.

2018-2019: Preclinical Characterization

Preclinical studies in animal models demonstrated that LY3437943 produced metabolic effects consistent with the engagement of all three target receptors:

• Weight loss exceeding that observed with single- or dual-agonist comparators
• Glycemic improvement despite the inclusion of GCGR agonism, confirming effective metabolic counterbalancing
• Liver fat reduction that was substantially greater than with GLP-1R agonists alone, consistent with GCGR-mediated hepatic fatty acid oxidation
• Favorable safety signals in toxicology studies sufficient to support progression to human trials

These preclinical findings provided the evidence base for the Investigational New Drug (IND) application submitted to the FDA, enabling the transition to human clinical trials.

Phase 1 Clinical Development (2019-2021)

2019: First-in-Human Study Initiation

Eli Lilly initiated the first-in-human Phase 1 clinical trial of retatrutide (then referred to by its internal designation LY3437943) in 2019. This study was designed as a single-ascending-dose and multiple-ascending-dose study in healthy volunteers and patients with type 2 diabetes.

The Phase 1 program established several critical parameters:

• Safety and tolerability: Confirmed that the drug was tolerated at doses expected to be pharmacologically active, with an adverse event profile consistent with the incretin-based therapy class (predominantly gastrointestinal)
• Pharmacokinetics: Characterized the absorption profile, terminal half-life (approximately 6 days), and exposure-response relationships that would inform Phase 2 dose selection
• Pharmacodynamics: Demonstrated preliminary evidence of glucose-lowering, appetite-reducing, and metabolic effects consistent with triple receptor agonism
• Dose range identification: Determined the dose range for evaluation in Phase 2 efficacy studies

2020-2021: Phase 1 Expansion and Phase 2 Preparation

The Phase 1 data, combined with the preclinical characterization, provided sufficient evidence to design the Phase 2 clinical program. Eli Lilly selected a range of doses and escalation schedules for Phase 2 evaluation, informed by the pharmacokinetic and pharmacodynamic relationships established in Phase 1.

Phase 2 Clinical Development (2021-2023)

2021: Phase 2 Trial Initiation

Two major Phase 2 clinical trials were initiated:

1. Phase 2 Obesity Trial: A randomized, double-blind, placebo-controlled trial evaluating multiple retatrutide doses (1 mg, 4 mg, 8 mg, and 12 mg) in adults with obesity (BMI of 30 or greater) or overweight (BMI of 27 or greater) with at least one weight-related comorbidity. The primary endpoint was percentage change in body weight at 48 weeks.

2. Phase 2 Type 2 Diabetes Trial: A randomized, double-blind, placebo-controlled trial evaluating retatrutide at multiple doses in adults with type 2 diabetes inadequately controlled on metformin alone or metformin plus a second agent. The primary endpoint was change in HbA1c at 36 weeks.

Both trials included dose-escalation arms designed to optimize tolerability, based on the Phase 1 finding that gradual titration significantly reduced gastrointestinal adverse events.

2022: First Peer-Reviewed Publication

A landmark publication in Cell Metabolism by Coskun and colleagues presented the preclinical characterization and early clinical data for retatrutide. This paper provided the first detailed public disclosure of the molecule’s receptor pharmacology, including its triple-agonist profile and the in vitro potency data at each target receptor. The publication established the scientific foundation for the molecule and generated significant interest in the metabolic research community.

Key significance: This was the first time the broader scientific community could evaluate the mechanistic rationale and early clinical evidence for a triple GIP/GLP-1/glucagon receptor agonist, a concept that had been discussed theoretically but never before demonstrated with a molecule in human clinical development.

2023: Phase 2 Results Published

The year 2023 marked a pivotal moment for retatrutide’s development with the publication of Phase 2 results from both major trials.

June 2023: Phase 2 Obesity Results (New England Journal of Medicine)

Jastreboff and colleagues published the results of the Phase 2 obesity trial in the New England Journal of Medicine, one of the most prestigious medical journals in the world. The results were remarkable:

• 12 mg dose: Approximately 24.2% mean body weight reduction at 48 weeks
• 8 mg dose: Approximately 22.8% mean reduction
• 4 mg dose: Approximately 17.5% mean reduction
• Placebo: Approximately 2.1% reduction

These weight loss figures were among the highest ever reported for a pharmacological intervention in obesity, exceeding the published results of both semaglutide 2.4 mg and tirzepatide at their respective highest doses over similar or longer treatment periods. The publication generated global media coverage and positioned retatrutide as a potential next-generation obesity treatment.

Secondary findings of note: The trial also reported dramatic reductions in liver fat content (up to approximately 82% relative reduction at the highest dose), improvements in blood pressure and lipid parameters, and a tolerability profile consistent with the incretin-based therapy class.

August 2023: Phase 2 Type 2 Diabetes Results (The Lancet)

Rosenstock and colleagues published the type 2 diabetes Phase 2 results in The Lancet. Key findings included:

• HbA1c reductions of up to approximately 2.0 percentage points, with a high proportion of participants achieving glycemic targets
• Significant weight loss in a diabetes population, where weight reduction is typically more difficult to achieve than in non-diabetic individuals
• Favorable metabolic improvements across multiple parameters

The combination of robust glycemic control and substantial weight loss in a type 2 diabetes population reinforced the potential of triple agonism as a treatment paradigm.

2023: Phase 3 Program Announced

Following the positive Phase 2 results, Eli Lilly announced the initiation of the Phase 3 TRIUMPH clinical program for retatrutide. The TRIUMPH program was designed to include multiple large, pivotal trials across different indications (obesity, type 2 diabetes, MASH) and patient populations, representing a comprehensive clinical development strategy aimed at supporting regulatory submissions for multiple indications.

Phase 3 Development and the TRIUMPH Program (2023-Present)

2023-2024: TRIUMPH Program Launches

The TRIUMPH Phase 3 program began enrolling participants across multiple trials. Key characteristics of the program:

• Scale: Thousands of participants across multiple trials and multiple countries
• Indications: Obesity/overweight, type 2 diabetes, and MASH
• Treatment duration: Extended beyond the 48 weeks studied in Phase 2, providing longer-term efficacy and safety data
• Diversity: Broader inclusion criteria compared with Phase 2, including more diverse patient populations, older adults, and patients with comorbidities

Eli Lilly invested substantially in the TRIUMPH program, reflecting the company’s confidence in retatrutide’s commercial potential and its strategic importance alongside the already-approved tirzepatide franchise.

2024: Additional Preclinical and Mechanistic Publications

In 2024, additional publications expanded the scientific understanding of retatrutide’s pharmacology. Coskun and colleagues published further mechanistic data characterizing the receptor interactions and metabolic effects of triple agonism, providing deeper insight into the synergistic mechanisms underlying the clinical results.

Eli Lilly also provided updates to the investment and medical communities regarding the progress of the TRIUMPH program, including enrollment status and expected timelines for data readouts.

2025: First Phase 3 Results — TRIUMPH-4

The year 2025 marked a major milestone with the first Phase 3 results. In December 2025, Eli Lilly announced the TRIUMPH-4 trial results via press release, reporting topline Phase 3 data. The full peer-reviewed publication is pending as of March 2026. TRIUMPH-4 evaluated retatrutide in adults with obesity and moderate-to-severe knee osteoarthritis over 68 weeks.

Key results:

• 12 mg dose: -28.7% mean body weight reduction at 68 weeks
• 9 mg dose: -26.4% mean body weight reduction
• Placebo: -2.1% reduction
• Body composition: DEXA sub-study confirmed approximately 75-80% of weight lost was fat mass
• Liver fat: Relative reductions of approximately 82% at the highest dose

The TRIUMPH-4 results confirmed and exceeded the Phase 2 efficacy signals. Notably, the trial also identified a new safety signal: dysesthesia (abnormal sensations such as tingling, numbness, or burning), reported in 8.8% of the 9 mg group and 20.9% of the 12 mg group versus 0.7% with placebo. This signal had not been prominent in Phase 2.

The Phase 3 dose escalation protocol was also disclosed (Giblin et al., Diabetes, Obesity and Metabolism, January 2026), revealing a refined 5-step escalation schedule: 2 mg → 4 mg → 6 mg → 9 mg → 12 mg, reaching maintenance by approximately week 17 — slower and more gradual than the Phase 2 protocol to improve tolerability.

2026: Phase 3 Program Continues

As of March 2026, the broader TRIUMPH Phase 3 program continues with multiple trials ongoing:

• TRIUMPH-4 results announced: First Phase 3 readout complete (December 2025, topline results via press release)
• Enrollment completion: Recruitment for the major obesity (TRIUMPH-1) and type 2 diabetes (TRANSCEND) trials has been substantially completed
• Additional readouts expected: TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRANSCEND results are anticipated throughout late 2026 and 2027
• Regulatory interactions: Eli Lilly has maintained ongoing dialogue with the FDA and other regulatory agencies regarding the development program and regulatory pathway

Looking Ahead: Remaining Milestones

The following milestones remain in retatrutide’s development pathway:

These projections remain subject to change based on trial outcomes, regulatory decisions, and manufacturing considerations.

The Broader Context

Retatrutide’s development timeline illustrates several broader trends in metabolic drug development. The progression from single-target GLP-1R agonists (exenatide, liraglutide, semaglutide) to dual-target GIP/GLP-1R agonists (tirzepatide) and now triple-target molecules (retatrutide) reflects an accelerating pace of innovation in the metabolic pharmacology field. Each generation has produced meaningfully greater efficacy, driven by the engagement of additional complementary metabolic pathways.

The speed of retatrutide’s development also reflects the maturity of the incretin-based therapy development model. Lessons learned from earlier molecules in the class, regarding dose escalation, endpoint selection, and regulatory strategy, have enabled a more efficient development process. The strong Phase 2 results have further accelerated the timeline by generating the confidence needed for a large-scale Phase 3 investment.

Summary

Retatrutide’s development spans from preclinical discovery in the late 2010s through Phase 1 (2019-2021), Phase 2 (2021-2023), and Phase 3 (2023-present). The landmark Phase 2 publications in the New England Journal of Medicine and The Lancet in 2023 established retatrutide as a potentially transformative metabolic therapy, prompting the launch of the comprehensive TRIUMPH Phase 3 program. In December 2025, the first Phase 3 topline results from TRIUMPH-4 were announced via press release, confirming -28.7% weight loss at 12 mg over 68 weeks. As of March 2026, additional Phase 3 trials are ongoing with further readouts expected throughout late 2026 and 2027, placing NDA submission in late 2026 (per Eli Lilly’s Q4 2025 earnings guidance) and potential regulatory approval in the mid-2027 to early 2028 timeframe.